<DOC>
	<DOCNO>NCT02420899</DOCNO>
	<brief_summary>The purpose study determine whether Rosuvastatin 10mg/d 20mg/d 36 week regress critical coronary atherosclerosis determine IVUS image Chinese Acute Coronary Syndrome ( ACS ) patient .</brief_summary>
	<brief_title>Different Doses Rosuvastatin Therapy Regression Critical Coronary Atherosclerosis ACS Patients</brief_title>
	<detailed_description>This prospective , open-label , parallel group study evaluate efficacy rosuvastatin 10mg/d 20mg/d critical coronary atherosclerosis Chinese ACS patient . The anticipated duration study approximately 36 week , Patients angiographic luminal diameter narrow non-culprit site 40 % -70 % enrol study site . The primary efficacy parameter percent change Total Atheroma Volume ( TAV ) critical coronary atherosclerosis 36 week treatment . For inclusion study subject fulfill follow criterion : 1 . Provision inform consent prior study specific procedures 2 . 18 75 year old ACS patient , male female 3 . The angiographic luminal diameter narrow non-culprit site 40 % -70 % 4. statin-naive , define receive statin therapy within 3 monthsThe primary efficacy variable study percent change TAV baseline rosuvastatin 10mg/d 20mg/d 36 week determine IVUS image . The secondary efficacy variable : - Change blood lipid level baseline 12th , 24th , 36nd week - Change inflammatory marker baseline 36nd week - Change Percent Atheroma Volume ( PAV ) determine IVUS image 36nd week</detailed_description>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>1.Provision informed consent prior study specific procedure ; 2.18 75 year old ACS patient , male female ; 3.The angiographic luminal diameter narrow nonculprit site 40 % 70 % ; 4.statinnaive , define receive statin therapy within 3 month ; 1 . Have receive statin therapy within 3 month ; 2 . The angiographic luminal diameter narrow coronary vessel 70 % ; 3 . Active liver disease , ALT≥3*ULN ; 4 . Renal function damage , CrCl＜30ml/min ; 5 . Myopathy ; 6 . Pregnancy , lactation female ; 7 . Using cyclosporine ; 8 . Patients uncontrolled triglyceride level TG≥5.65 mmol／L ; 9 . Poorly control diabetes ( HbA1c≥10 % ）Hypersensitivity rosuvastatin recipient .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>IVUS</keyword>
	<keyword>ACS</keyword>
</DOC>